Value proposition

Harnessing the power of chemical novelty, diversity and 3-dimensionality to develop innovative small molecule drugs

PharmEnable is a biopharmaceutical company utilizing AI to discover effective small-molecule medicines for disease targets that are inaccessible to antibodies. With our proprietary AI-enabled drug discovery platform, chemSEEK, we explore new chemical spaces and discover novel small molecules with antibody-like specificity and selectivity. We are developing a pipeline of wholly owned therapeutics with initial focus on oncology and neurology. We also engage in drug discovery partnerships across a range of disease areas where accessing the target poses a significant challenge. PharmEnable is based in Cambridge, UK, and is a spinoff of the University of Cambridge.

Discover how we are reimagining small molecule therapeutics through AI at pharmenabletx.com and connect with us on LinkedIn.